Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infection/Inflammatory Lesions Clear all
Enrolling by invitation Not applicable Interventional

Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems

NCT07296263
View directory record Official record
Conditions
Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
Interventions
Portable MRI (pMRI), Gadolinium-Based Contrast Agent (GBCA)
Device · Drug
Lead sponsor
Hyperfine
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Altamonte Springs, Florida • Amherst, New York • Abington, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 26, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 26, 2026, 1:22 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03713632
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
San Diego, California • Whittier, California • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 26, 2026, 1:22 PM EDT
Completed No phase listed Observational

ABTHERA ADVANCE™ Use Without Wittman Patch

NCT04986943
View directory record Official record
Conditions
Necrotizing Pancreatitis
Interventions
Using ABTHERA Advance without a Wittmann Patch
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Years and older
Enrollment
3 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jun 26, 2026, 1:22 PM EDT